Skip to main content

Table 2 Toxicity (n = 31)

From: A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

 

Number of patients, n (%)

 

Grade 1

Grade 2

Grade 3

Grade 4

All grades

Grade 3/4

Hematological adverse events

 Anemia

4

4

2

0

10 (32)

2 (6)

 Thrombocytopenia

7

1

0

0

8 (26)

0 (0)

 Neutropenia

4

1

1

0

6 (19)

1 (3)

 Febrile neutropenia

–

–

1

0

1 (3)

1 (3)

Non-hematological adverse events

 Stomatitis

7

8

8

0

23 (74)

8 (26)

 Fatigue

13

10

0

–

23 (74)

0 (0)

 Anorexia

10

9

2

0

21 (68)

2 (6)

 Diarrhea

8

4

3

0

15 (48)

3 (10)

 Skin pigmentation

8

4

0

0

12 (39)

0 (0)

 Hypertension

7

2

1

0

10 (32)

1 (3)

 Nausea

8

1

0

–

9 (29)

0 (0)

 Epistaxis

9

0

0

0

9 (29)

0 (0)

 Watering eyes

4

1

0

–

5 (16)

0 (0)

 Vomiting

3

1

0

0

4 (13)

0 (0)

  1. The most common toxicities of all grade were stomatitis (74 %), fatigue (74 %), anorexia (68 %) and diarrhea (48 %)
  2. The major grade 3–4 toxicities were stomatitis (26 %) and diarrhea (10 %)